JPWO2019213446A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019213446A5 JPWO2019213446A5 JP2020561780A JP2020561780A JPWO2019213446A5 JP WO2019213446 A5 JPWO2019213446 A5 JP WO2019213446A5 JP 2020561780 A JP2020561780 A JP 2020561780A JP 2020561780 A JP2020561780 A JP 2020561780A JP WO2019213446 A5 JPWO2019213446 A5 JP WO2019213446A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- item
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims description 268
- 229920001184 polypeptide Polymers 0.000 claims description 114
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 114
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 114
- 102000037865 fusion proteins Human genes 0.000 claims description 81
- 108020001507 fusion proteins Proteins 0.000 claims description 81
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 67
- 235000001014 amino acid Nutrition 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 53
- 125000005647 linker group Chemical group 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 30
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 108060003951 Immunoglobulin Proteins 0.000 claims description 18
- 102000018358 immunoglobulin Human genes 0.000 claims description 18
- 208000007502 anemia Diseases 0.000 claims description 10
- 210000003205 muscle Anatomy 0.000 claims description 9
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000000833 heterodimer Substances 0.000 claims description 4
- 230000036755 cellular response Effects 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 42
- 239000011230 binding agent Substances 0.000 description 38
- 108091033319 polynucleotide Proteins 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 239000012634 fragment Substances 0.000 description 14
- 102000016970 Follistatin Human genes 0.000 description 7
- 108010014612 Follistatin Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 208000024985 Alport syndrome Diseases 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 2
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 208000003215 hereditary nephritis Diseases 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666548P | 2018-05-03 | 2018-05-03 | |
| US62/666,548 | 2018-05-03 | ||
| US201862779992P | 2018-12-14 | 2018-12-14 | |
| US62/779,992 | 2018-12-14 | ||
| PCT/US2019/030475 WO2019213446A1 (en) | 2018-05-03 | 2019-05-02 | NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522795A JP2021522795A (ja) | 2021-09-02 |
| JP2021522795A5 JP2021522795A5 (https=) | 2022-05-13 |
| JPWO2019213446A5 true JPWO2019213446A5 (https=) | 2022-05-13 |
Family
ID=68386156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561780A Pending JP2021522795A (ja) | 2018-05-03 | 2019-05-02 | ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12168683B2 (https=) |
| EP (1) | EP3788067A4 (https=) |
| JP (1) | JP2021522795A (https=) |
| AU (1) | AU2019262143A1 (https=) |
| CA (1) | CA3099325A1 (https=) |
| WO (1) | WO2019213446A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019213442A1 (en) | 2018-05-03 | 2019-11-07 | Acceleron Pharma Inc. | MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
| WO2021092079A1 (en) | 2019-11-05 | 2021-05-14 | Acceleron Pharma Inc. | Treatments for systemic sclerosis |
| US20240277807A1 (en) * | 2021-06-11 | 2024-08-22 | Acceleron Pharma Inc. | Actrii proteins and uses thereof |
| WO2023049917A1 (en) * | 2021-09-27 | 2023-03-30 | Zoetis Services Llc | ANTI- TGFβ1,2,3 ANTIBODIES AND THERAPEUTIC USES THEREOF |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2449753T3 (es) | 2007-03-19 | 2014-03-21 | National Research Council Of Canada | Proteínas de fusión que comprenden dos dominios de unión tgf-beta |
| CA3083324A1 (en) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| NZ707477A (en) * | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| US10227392B2 (en) * | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| US11440949B2 (en) | 2016-10-05 | 2022-09-13 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| BR112019006993A2 (pt) | 2016-10-05 | 2019-09-03 | Acceleron Pharma Inc | heteromultímeros de alk4:actriib e usos dos mesmos |
-
2019
- 2019-05-02 CA CA3099325A patent/CA3099325A1/en active Pending
- 2019-05-02 US US17/052,783 patent/US12168683B2/en active Active
- 2019-05-02 EP EP19796602.1A patent/EP3788067A4/en active Pending
- 2019-05-02 WO PCT/US2019/030475 patent/WO2019213446A1/en not_active Ceased
- 2019-05-02 AU AU2019262143A patent/AU2019262143A1/en not_active Abandoned
- 2019-05-02 JP JP2020561780A patent/JP2021522795A/ja active Pending
-
2024
- 2024-10-23 US US18/924,487 patent/US20250333477A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101522954B1 (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| EP2847229B1 (en) | Single domain binding molecule | |
| JP2019137675A5 (https=) | ||
| JP2023123649A5 (https=) | ||
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2021522795A5 (https=) | ||
| KR20170049319A (ko) | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 | |
| CN119032104A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| US20180280474A1 (en) | Treatment of bile acid disorders | |
| JP2025124718A5 (https=) | ||
| JP2021522793A5 (https=) | ||
| JPWO2021185361A5 (https=) | ||
| JPWO2019213446A5 (https=) | ||
| JPWO2019213442A5 (https=) | ||
| JP2025116068A (ja) | 腎臓活性融合タンパク質及びそれを使用する治療方法 | |
| JPWO2022130342A5 (https=) | ||
| EP4559932A1 (en) | Multispecific antibody and use thereof | |
| JPWO2022129560A5 (https=) | ||
| CN112969477B (zh) | 改善肽的血液动力学的方法 | |
| JPWO2023070056A5 (https=) | ||
| JP7829127B2 (ja) | 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質 | |
| JPWO2022150788A5 (https=) | ||
| JP2022504392A5 (https=) | ||
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| JPWO2021107603A5 (https=) |